Name : SARS-COV-2 Spike RBD (N501Y,K417N,E484K) Protein
Product Source :
Recombinant SARS-COV-2 Spike RBD (N501Y,K417N,E484K) Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Arg319-Phe541(N501Y,K417N,E484K).[Accession | QHD43416.1]
Molecular Weight :
The protein has a predicted MW of 26.2 kDa. Due to glycosylation, the protein migrates to 30-40 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE SARS-COV-2 Spike RBD (N501Y,K417N,E484K) on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of SARS-COV-2 Spike RBD (N501Y,K417N,E484K) is greater than 95% as determined by SEC-HPLC. ELISA Data Immobilized SARS-COV-2 Spike RBD (N501Y,K417N,E484K) , His Tag at 0.5μg/ml (100ul/Well) on the plate. Dose response curve for Human ACE2, hFc Tag with the EC50 of 9.9ng/ml determined by ELISA.
Background :
The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.
Synonyms :
S protein RBD; S glycoprotein RBD; Spike protein RBD
References & Citations :
(1)Larry J Anderson, Ralph S Baric. Emerging Human Coronaviruses – Disease Potential and Preparedness[J]. N Engl J Med, 2012, 367(19):1850-1852.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
IL-22BP/IL-22RA2 Proteinmanufacturer
Progranulin/PGRN Proteincustom synthesis
Popular categories:
Ephrin A2
Integrin alpha V beta 3